Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIB7734 (Daxdilimab) Phase 1b in Autoimmune Diseases
NCT03817424Phase 1Completed
- Sponsor
- Amgen
- Start
- Dec 2018
- Primary completion
- Jul 2020
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of daxdilimab in systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), Sjogren's syndrome and 3 more (4 arms), sponsored by Amgen. Primary endpoints: Treatment-Emergent Adverse Events and Adverse Events of Special Interest. Started Dec 2018; status: completed.
02
Drugs
daxdilimab
03
Conditions
systemic lupus erythematosus (SLE)cutaneous lupus erythematosus (CLE)Sjogren's syndromesystemic sclerosis (SSc)polymyositis (PM)
Beyond the preview
Go deeper on NCT03817424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03817424.